Direct factor Xa inhibitors prevent deep venous thromboembolism after total knee arthroplasty: A Meta-analysis

doi:10.3969/j.issn.2095-4344.2013.17.014

Abstract

Abstract:

BACKGROUND: Direct factor Xa inhibitors play an important role in the prevention and treatment of venous thromboembolism. However, the efficacy and safety of direct factor Xa inhibitors in the prevention of venous thromboembolism in the patients that undergoing total knee arthroplasty is not clear when compared with the low-molecular-weight heparin.
OBJECTIVE: To explore the pros and cons of direct factor Xa inhibitor and low-molecular-weight heparin in the prevention of deep venous thromboembolism after total knee arthroplasty.
METHODS: A computer-based online search was performed in MEDLINE database, EMBASE database, Cochrane Library, CBM database and CNKI database, supplemented by manual searches to find the randomized trials on the comparison of direct factor Xa inhibitor and low-molecular-weight heparin in the prevention of deep venous thromboembolism after total knee arthroplasty. The quality of included studies was evaluated by quality assessment standards proposed by the Cochrane Handbook, and data analysis was performed with Stata12.0 software.
RESULTS AND CONCLUSION: Compared with low-molecular-weight heparin, direct factor Xa inhibitor can significantly reduce the incidence of symptomatic deep venous thromboembolism without increasing bleeding risk (P < 0.05), and there were no significant differences in mortality rate during follow-up period and pulmonary embolism between two groups (P > 0.05). In the prevention of deep venous thromboembolism after total knee arthroplasty, direct factor Xa inhibitor is more secure, effective and convenient than low-molecular-weight heparin.

Key words: bone and joint implants, evidence-based medicine, direct factor Xa inhibitor, low molecular weight, heparin, total knee arthroplasty, venous thrombosis, Meta-analysis

CLC Number:

R318

Chen Xue-qing, Jia Jian. Direct factor Xa inhibitors prevent deep venous thromboembolism after total knee arthroplasty: A Meta-analysis[J]. Chinese Journal of Tissue Engineering Research, 2013, 17(17): 3140-3147.

Figures/Tables 3

References

[1] Colwell CW Jr. Rationale for thromboprophylaxis in lower joint arthroplasty. Am J Orthop (Belle Mead NJ). 2007;36(9 Suppl): 11-13.

[2] Dahl OE. Continuing out-of-hospital prophylaxis following major orthopaedic surgery: what now? Haemostasis. 2000;30 Suppl 2:82-83,101-105.

[3] Ma YH, Zhang S. Zhongguo Xiandai Yixue Zazhi. 2010;7(12):7.马云辉,张寿.骨科深静脉血栓形成药物预防的研究进展[J].中国现代医学杂志,2010,7(12):7.

[4] Edelsberg J, Ollendorf D, Oster G. Venous thromboembolism following major orthopedic surgery: review of epidemiology and economics. Am J Health Syst Pharm. 2001;58 Suppl 2: S4-13.

[5] Chinese Society of Orthopedics. Zhonghua Chuangshang Guje Zazhi. 2012;14(6):1-3.中华医学会骨科学分会创伤骨科学组.中国骨科创伤患者围手术期静脉血栓栓塞症预防的专家共识[J].中华创伤骨科杂志, 2012,14(6):1-3.

[6] Fu ZH. Shiyong Yiyao Zazhi. 2003;20(12):941-942.付志厚.髋膝关节置换术后下肢深静脉血栓形成的防治[J].实用医药杂志,2003,20(12):941-942.

[7] Li XL. Lu WJ, YU NS, et al. Zhonghua Chuangshang Guke Zazhi. 2000;3(1):37-39.李晓林,卢伟杰,余楠生,等.低分子量肝素预防髋膝术后下肢深静脉血栓形成[J].中华创伤骨科杂志,2000,3(1):37-39.

[8] Miric A, Lombardi P, Sculco TP. Deep vein thrombosis prophylaxis: a comprehensive approach for total hip and total knee arthroplasty patient populations. Am J Orthop (Belle Mead NJ). 2000;29(4):269-274.

[9] Jing GW, Ye SN, Yang SH. Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu. 2011;15(22):4028-4031.靖光武,叶树楠,杨述华.髋关节置换后利伐沙班与低分子肝素预防下肢深静脉血栓的比较[J].中国组织工程研究与临床康复, 2011,15(22):4028-4031.

[10] Tian GX, Wei WL, Zhang L. Zhongguo Xunzheng Xinxueguan Yixue Zazhi. 2011;3(5):403-406.田国祥,魏万林,张灵.后华法林时代口服抗凝新秀:达比加群、利伐沙班、阿哌沙班[J].中国循证心血管医学杂志,2011,3(5):403-406.

[11] Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361(6):594-604.

[12] Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010; 375(9717):807-815.

[13] Lassen MR, Davidson BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost. 2007;5(12):2368-2375.

[14] Turpie AG, Bauer KA, Davidson BL, et al. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost. 2009;101(1): 68-76.

[15] Lassen MR, Davidson BL, Gallus A, et al. A phase II randomized, double-blind, ?ve-arm, parallel-group, dose-response study of a new oral directly-acting factor Xa inhibitor, razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery-on behalf of the razaxaban investigators. Blood. 2003;102(11 Pt 1):15a.

[16] Turpie AG, Fisher WD, Bauer KA, et al. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost. 2005;3(11): 2479-2486.

[17] Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776-2786.

[18] Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373(9676):1673-1680.

[19] Fuji T, Wang C, Fujita S, et al. Edoxaban versus enoxaparin for thromboprophylaxis after total knee replacement: the STARS E-3 trial. Milan: 21st International Congress on Thrombosis, 2010.

[20] Weitz JI, Cao C, Eriksson BI, et al. A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost. 2010;104(6):1150-1157.

[21] Li PJ, Gao YL, Wang DC, et al. Zhongguo Jiaoxing Waike Zazhi. 2012;20(11):998-1000.李佩佳,高玉镭,王东辰,等.利伐沙班与低分子肝素在预防人工全膝关节置换术后深静脉血栓形成的分析[J].中国矫形外科杂志,2012,20(11):998-1000.

[22] Ji SJ, Zhou YX. Guoji Guke Xue Zazhi. 2010;31(6):336-339.及松洁,周一新.假体设计和手术技术对全膝关节置换术后关节活动的影响[J].国际骨科学杂志,2010,31(6):336-339.

[23] Wang WH, Tian SQ, Zhang CL, et al. Zhongguo Jiaoxing Waike Zazhi. 2012;20(7):598-602.王文浩,田少奇,张才龙,等.同期双侧与单侧全膝关节置换治疗膝骨关节炎的比较[J].中国矫形外科杂志,2012,20(7):598-602.

[24] Tian H. Linchuang Yaowu Zhiliao Zazho. 2009;7(3):3134.田华.关节置换术后深静脉血栓形成的预防与治疗[J].临床药物治疗杂志,2009,7(3):3134.

[25] Yan WQ, Wang K, Han SS, et al. Zhonghua Guanjie Waike Zazhi. 2012;6(2):37-39.严文琪,王凯,韩生寿,等.利伐沙班预防高原红细胞增多症患者全膝关节置换术后深静脉血栓发生的临床研究[J].中华关节外科杂志,2012,6(2):37-39.

[26] Wang GH, Shen DS, Xiong W. Zhongguo Xinyao Zazhi. 2009; 18(6):494-496.王国华,申东升,熊维.抗凝血新药利伐沙班[J].中国新药杂志, 2009,18(6):494-496.

[27] Eikelboom JW, Weitz JI. Selective factor Xa inhibition for thromboprophylaxis. Lancet. 2008;372(9632):6-8.

[28] Qu D. Qilu Yaoshi. 2012;31(2):102-104.曲迪.抗凝血Xa因子直接抑制药研究进展[J].齐鲁药事,2012, 31(2):102-104.